Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease

Author(s): Ana C. Brett, Tatiana R. Rosenstock, A. Cristina Rego

Journal Name: Current Drug Targets

Volume 15 , Issue 3 , 2014

Become EABM
Become Reviewer
Call for Editor


Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.

Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 03 February, 2014
Page: [313 - 334]
Pages: 22
DOI: 10.2174/1389450114666131124140704
Price: $65

Article Metrics

PDF: 49